Skip to main content
SpringerLink
Log in
Book cover

Image-Guided Cancer Therapy pp 101–113Cite as

Embolic Therapies

  • Reference work entry
  • First Online:

  • 1499 Accesses

Abstract

Primary and secondary liver cancers pose a challenge in terms of treatment options for the following reasons: (1) most patients are unresectable at presentation not only due to tumor stage but also because of comorbidities (cirrhosis) and (2) there exist limitations in systemic chemotherapy (adverse events) and external radiation (dose delivered to normal tissue). Given this, embolic therapies involve the transarterial delivery of high-dose toxic material directly to the tumor and thereby sparing the normal hepatic tissue as well as rest of the body from possible adverse reactions. Embolic therapies require knowledge of vascular anatomy, technical aspects of targeting the tumor for delivery of toxic material, physical properties of available devices, and clinical aspects of patient selection, response assessment, patient monitoring, and complications. Embolic therapy includes bland embolization, chemoembolization (conventional and drug-eluting beads), and radioembolization. This chapter covers the basic concepts associated with each of these treatment modalities. This chapter also gives a brief overview of utilization of embolic therapies in extrahepatic neoplasms.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):S74–83.

    Article  PubMed  Google Scholar 

  2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  4. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.

    Article  CAS  PubMed  Google Scholar 

  5. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507 e492.

    Article  PubMed  Google Scholar 

  6. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.

    Article  CAS  PubMed  Google Scholar 

  7. Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010;255(3):955–65.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.

    Article  PubMed  Google Scholar 

  9. Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10(1):12–29.

    Article  PubMed  Google Scholar 

  10. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30(4):571–92.

    Article  PubMed  Google Scholar 

  11. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005;16(7):911–35.

    Article  PubMed  Google Scholar 

  12. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641–57.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.

    Article  PubMed  Google Scholar 

  14. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  15. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248(4):617–25.

    PubMed  Google Scholar 

  16. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–8.

    Article  CAS  PubMed  Google Scholar 

  17. Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S62–73.

    Article  CAS  PubMed  Google Scholar 

  18. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27(34):5734–42.

    Article  CAS  PubMed  Google Scholar 

  19. Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009;34(5):566–81.

    Article  PubMed  Google Scholar 

  20. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303(11):1062–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rhee TK, Naik NK, Deng J, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol. 2008;19(8):1180–6.

    Article  PubMed  Google Scholar 

  22. Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic–pathologic correlation. J Hepatol. 2011;54(4):695–704.

    Article  PubMed  Google Scholar 

  23. Markowitz J. The hepatic artery. Surg Gynecol Obstet. 1952;95(5):644–6.

    CAS  PubMed  Google Scholar 

  24. Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol. 1998;9(5):822–8.

    Article  CAS  PubMed  Google Scholar 

  25. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47–54.

    Article  PubMed  Google Scholar 

  26. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222–6.

    Article  CAS  PubMed  Google Scholar 

  27. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27(6):1578–83.

    Article  CAS  PubMed  Google Scholar 

  28. Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008;19(6):862–9.

    Article  PubMed  Google Scholar 

  29. Maluccio MA, Covey AM, Schubert J, et al. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer. 2006;107(7):1617–23.

    Article  PubMed  Google Scholar 

  30. Xia J, Ren Z, Ye S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol. 2006;59(3):407–12.

    Article  PubMed  Google Scholar 

  31. Eksborg S, Cedermark BJ, Strandler HS. Intrahepatic and intravenous administration of adriamycin–a comparative pharmacokinetic study in patients with malignant liver tumours. Med Oncol Tumor Pharmacother. 1985;2(1):47–54.

    CAS  PubMed  Google Scholar 

  32. Ensminger W. Hepatic arterial chemotherapy for primary and metastatic liver cancers. Cancer Chemother Pharmacol. 1989;23(Suppl):S68–73.

    Article  PubMed  Google Scholar 

  33. Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics. 1994;14(3):623–43. quiz 645–626.

    Article  CAS  PubMed  Google Scholar 

  34. Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park). 1994;8(4):77–84. discussion 84, 89–90 passim.

    CAS  Google Scholar 

  35. Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol. 1999;10(6):793–8.

    Article  CAS  PubMed  Google Scholar 

  36. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117(7):1498–505.

    Article  CAS  PubMed  Google Scholar 

  38. Geschwind J, Hong K, Georgiades C. Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco; 26–28 Jan 2006.

    Google Scholar 

  39. Liapi E, Geschwind J-F, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008;190(1):67–73.

    Article  PubMed  Google Scholar 

  40. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15(3):289–91.

    Article  PubMed  Google Scholar 

  41. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007;18(8):957–63.

    Article  PubMed  Google Scholar 

  42. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16(3):353–61.

    Article  PubMed  Google Scholar 

  43. Murakami T, Ishimaru H, Sakamoto I, et al. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol. 2007;30(4):696–704.

    Article  PubMed  Google Scholar 

  44. Kagawa T, Koizumi J, Kojima S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116(15):3638–44.

    Article  PubMed  Google Scholar 

  45. Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15(11):3169–77.

    Article  PubMed  Google Scholar 

  46. Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology. 1995;197(3):812–8.

    Article  CAS  PubMed  Google Scholar 

  47. Kim HK, Chung YH, Song BC, et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol. 2001;32(5):423–7.

    Article  CAS  PubMed  Google Scholar 

  48. Belli L, Magistretti G, Puricelli GP, Damiani G, Colombo E, Cornalba GP. Arteritis following intra-arterial chemotherapy for liver tumors. Eur Radiol. 1997;7(3):323–6.

    Article  CAS  PubMed  Google Scholar 

  49. Hong K, Georgiades CS, Geschwind JF. Technology insight: Image-guided therapies for hepatocellular carcinoma–intra-arterial and ablative techniques. Nat Clin Pract Oncol. 2006;3(6):315–24.

    Article  PubMed  Google Scholar 

  50. Constantin M, Fundueanu G, Bortolotti F, Cortesi R, Ascenzi P, Menegatti E. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharm. 2004;285(1–2):87–96.

    Article  CAS  PubMed  Google Scholar 

  51. Gonzalez MV, Tang Y, Phillips GJ, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med. 2008;19(2):767–75.

    Article  CAS  PubMed  Google Scholar 

  52. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81.

    Article  CAS  PubMed  Google Scholar 

  53. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009;15(6):526–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–51.

    Article  PubMed  Google Scholar 

  55. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8.

    Article  PubMed  Google Scholar 

  56. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology. 2002;224(2):542–7.

    Article  PubMed  Google Scholar 

  57. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt 2):S223–9.

    Article  PubMed  Google Scholar 

  58. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94(7):572–86.

    Article  CAS  PubMed  Google Scholar 

  59. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2007;47(1):71–81.

    Article  Google Scholar 

  60. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.

    Article  CAS  PubMed  Google Scholar 

  61. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.

    Article  PubMed  Google Scholar 

  62. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.

    Article  CAS  PubMed  Google Scholar 

  63. Kennedy A, Coldwell D, Nutting C, Overton C, Sailer S. Liver brachytherapy for unresectable colorectal metastases: US results 2000–2004. Paper presented at: ASCO GI Symposium. Miami; 27–29 Jan 2005.

    Google Scholar 

  64. Goin JE, Dancey JE, Hermann GA, Sickles CJ, Roberts CA, MacDonald JS. Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: a dose-ranging study. World J Nuc Med. 2003;2:216–25.

    Google Scholar 

  65. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106.

    Article  CAS  PubMed  Google Scholar 

  66. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94.

    Article  CAS  PubMed  Google Scholar 

  67. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247(6):1029–35.

    Article  PubMed  Google Scholar 

  68. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–9.

    Article  PubMed  Google Scholar 

  69. Coldwell D, Nutting C, Kennedy AK. Treatment of hepatic metastases from breast cancer with yttrium-90 SIR-Spheres radioembolization. Paper presented at: Society of Interventional Radiology Annual Meeting. New Orleans; 31 Mar–5 Apr 2005.

    Google Scholar 

  70. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology. 2008;247(2):507–15.

    Article  PubMed  Google Scholar 

  71. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16(12):1627–39.

    Article  PubMed  Google Scholar 

  72. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65(2):412–25.

    Article  CAS  PubMed  Google Scholar 

  73. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16(7):937–45.

    Article  PubMed  Google Scholar 

  74. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112(7):1538–46.

    Article  PubMed  Google Scholar 

  75. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375–82.

    Article  PubMed  Google Scholar 

  76. Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with (90)yttrium microspheres. Dig Dis Sci. 2008;53(9):2556–63.

    Article  CAS  PubMed  Google Scholar 

  77. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada; 2004.

    Google Scholar 

  78. Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18(4):553–61. quiz 562.

    Article  PubMed  Google Scholar 

  79. Carretero C, Munoz-Navas M, Betes M, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol. 2007;102(6):1216–20.

    Article  PubMed  Google Scholar 

  80. Murthy R, Eng C, Krishnan S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18(12):1588–91.

    Article  PubMed  Google Scholar 

  81. Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31(3):566–73.

    Article  CAS  PubMed  Google Scholar 

  82. Nakashima T, Mihoki T, Ono T, Umeno H, Tanaka N. Selective (intra-arterial), rapid infusion chemo-radiotherapy to preserve the larynx in advanced laryngeal carcinoma: preliminary results. J Laryngol Otol Suppl. 2009;31:30–4.

    Article  Google Scholar 

  83. Lang EK, Sullivan J. Management of primary and metastatic renal cell carcinoma by transcatheter embolization with iodine 125. Cancer. 1988;62(2):274–82.

    Article  CAS  PubMed  Google Scholar 

  84. Li MJ, Zhou YB, Huang Y, et al. A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy. J Vasc Interv Radiol. 2011;22(3):279–86.

    Article  PubMed  Google Scholar 

  85. Rossi G, Mavrogenis AF, Rimondi E, et al. Selective arterial embolisation for bone tumours: experience of 454 cases. Radiol Med. 2011;116(5):793–808.

    Article  CAS  PubMed  Google Scholar 

  86. Roche PH, Paris J, Regis J, et al. Management of invasive juvenile nasopharyngeal angiofibromas: the role of a multimodality approach. Neurosurgery. 2007;61(4):768–77. discussion 777.

    Article  PubMed  Google Scholar 

  87. Lee SY, Hsu HH, Chen YC, et al. Embolization of renal angiomyolipomas: short-term and long-term outcomes, complications, and tumor shrinkage. Cardiovasc Intervent Radiol. 2009;32(6):1171–8.

    Article  PubMed  Google Scholar 

  88. Watkinson A, Nicholson A. Uterine artery embolisation to treat symptomatic uterine fibroids. BMJ. 2007;335(7622):720–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Northwestern Memorial Hospital, 676 N. St. Claire, Ste. 800, Chicago, IL, 60611, USA

    Ahsun Riaz, Khairuddin Memon, Robert J. Lewandowski & Riad Salem

Authors
  1. Ahsun Riaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khairuddin Memon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. Lewandowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riad Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahsun Riaz .

Editor information

Editors and Affiliations

  1. The Warren Alpert Medical School of Brown University, Department of Diagnostic Imaging Rhode Island Hospital, Providence, Rhode Island, USA

    Damian E. Dupuy

  2. Department of Surgery and Radiology Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Yuman Fong

  3. McMullen Consulting, LLC, Surprise, Arizona, USA

    William N. McMullen

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this entry

Cite this entry

Riaz, A., Memon, K., Lewandowski, R.J., Salem, R. (2013). Embolic Therapies. In: Dupuy, D., Fong, Y., McMullen, W. (eds) Image-Guided Cancer Therapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0751-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0751-6_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0750-9

  • Online ISBN: 978-1-4419-0751-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation